Product Name: Tenofovir Disoproxil Fumarate CAS NO:202138-50-9
Chemical & Physical Properties:
Appearance : white to beige powder
Boiling Point:642.7℃ at 760 mmHg
Tenofovir fumarate is a nucleotide antiviral drug developed and marketed by Gilead in the United States. It was approved by the FDA in 2001 for the treatment of human immunodeficiency virus (HIV) infection. It was launched in the European Union in 2002 and approved for the treatment of HIV-1 and chronic hepatitis B. Tenofovir disoproxil fumarate, as a nucleotide reverse transcriptase inhibitor, is an orally-opened ring-opening nucleotide phosphate prodrug. After oral absorption, it quickly transforms into tenofovir and exerts its efficacy. Due to its high bioavailability, precise curative effect and good tolerance, TDF has now become the recommended first-line anti-HIV drug with the highest sales.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.